A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome

Registry ID

EUCTR2010-019302-16

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Royal Brompton and Harefield NHS Foundation Trust

Start date

2010-09-13

Completion date

2018-03-12

Last update

2026-08-16

Conditions

• Marfan Syndrome

Summary

Does the angiotensin II receptor antagonist, Irbesartan, reduce the rate of aortic dilatation in patients with Marfan Syndrome compared to placebo?

Locations

• , , UK

Related clinical trials

• PregnAncy-Related Aortic DISsEction in China
• Fibroblasts and Thoracic Aortic Aneurysms: in Vitro Characterization in With Marfan Syndrome and Genetic Aortic Diseases
• National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
• Biological Collection for Marfan and Related Syndromes
• Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome
• Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices

View on source registry